bioAffinity Technologies Inc (BIAF) Stock Analysis
Verdict: AVOID
Low float fuels acute short-term spikes, but an 8-month cash runway and annual burn of $9.4M signal severe dilution risk.
Investment score: 21/100
Analysis as of
Is bioAffinity Technologies Inc stock worth reviewing? AI model thesis
The AI model classifies BIAF as AVOID due to alarming cash depletion, declining TTM revenue (-35.75%), and high likelihood of near-term dilutive equity financing.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 20/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
bioAffinity Technologies Inc opportunities and risks
What speaks for BIAF
- CyPath Lung Commercial Expansion
What speaks against BIAF
- Imminent Dilutive Equity Financing
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| BIAF | n/a | 0.7x | n/a | -39.6% | -257.3% | -281.6% |
| ADTX | n/a | 487.3x | n/a | 19.9% | -362385.7% | -265.9% |
| AIM | n/a | 8.4x | 0.4x | -125.3% | -15021.1% | -896.7% |
| HCWB | n/a | 0.2x | n/a | 95.9% | -73.2% | -1040.6% |
| AQB | n/a | 0.0x | n/a | 0.0% | 0.0% | -118.1% |
| XBIO | n/a | 3.0x | n/a | 100.0% | -75.9% | -23.8% |
| Peer median | n/a | 3.0x | n/a | 19.9% | -75.9% | -265.9% |
Frequently asked questions about bioAffinity Technologies Inc (BIAF)
Is BIAF stock a good investment?
The cached TradeMates AI model rates bioAffinity Technologies Inc as AVOID with an investment score of 21/100. The AI model classifies BIAF as AVOID due to alarming cash depletion, declining TTM revenue (-35.75%), and high likelihood of near-term dilutive equity financing. This is algorithmic model output, not personal investment advice.
Is BIAF stock a buy?
The TradeMates model verdict for BIAF is AVOID with an investment score of 21/100. Treat this as a model signal to review, not a personal buy recommendation.